Filing Flows › Monte Rosa Therapeutics (GLUE) › Q3 2026 › vs Q3 2025
Monte Rosa Therapeutics (GLUE) Q3 2026 vs Q3 2025 (year over year)
Monte Rosa Therapeutics's revenue rose $41.6M (+326%) from $12.8M in Q3 2025 to $54.4M in Q3 2026.
Monte Rosa Therapeutics, Q3 2026: revenue $54.4M (+326% year over year), operating margin -3.6%, net earnings $3.1M, operating cash flow −$41.0M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $54.4M | $12.8M | $41.6M | +326% |
| Other income, net | $5.7M | $2.7M | $3.0M | +110% |
| Costs & expenses | $60.1M | $45.7M | $14.3M | +31% |
| Operating costs | $56.3M | $45.7M | $10.6M | +23% |
| Income tax | $716K | −$3.2M | $3.9M | — |
| Net earnings | $3.1M | −$27.1M | $30.1M | — |
| Research & development | $45.4M | $36.7M | $8.7M | +24% |
| General & admin | $10.9M | $9.1M | $1.9M | +21% |
| Operating cash sources | $53.2M | −$120M | $174M | — |
| Depreciation & amortization | $2.9M | $2.7M | $127K | +5% |
| Share-based compensation | $6.3M | $4.4M | $2.0M | +45% |
| Cash used in operations | $41.0M | −$100M | $141M | — |
| Working capital & other | $53.2M | −$120M | $174M | — |
Questions
How much did Monte Rosa Therapeutics's revenue grow year over year in Q3 2026?
Monte Rosa Therapeutics's revenue rose $41.6M (+326%) from $12.8M in Q3 2025 to $54.4M in Q3 2026.